Arrowhead Pharmaceuticals, Inc. (ARWR): A Bull Case Theory

Company Overview - Arrowhead Pharmaceuticals, Inc. is a leading RNAi-focused biotechnology company, with its flagship candidate plozasiran targeting the ApoC3 gene to reduce plasma triglyceride levels [2] - The company utilizes its proprietary TRiM™ platform for low-dose, quarterly subcutaneous injections, which allows for the silencing of ApoC3 in liver cells [2] Pipeline and Development - A New Drug Application for plozasiran has been filed for Familial Chylomicronemia Syndrome (FCS), with a PDUFA action date set for November 18, 2025, while Phase 3 trials are ongoing for Severe Hypertriglyceridemia (sHTG) [3] - Arrowhead is also advancing other pipeline candidates, including fazirsiran for Alpha-1 antitrypsin deficiency and early-stage obesity programs ARO-INHBE and ARO-ALK7, demonstrating the versatility of its RNAi platform [3] Financial Position - The company has a robust balance sheet with approximately $900 million in cash and equivalents, providing sufficient funding for its clinical programs [4] - Revenue is primarily generated from partnerships, with recent payments from Sanofi and Sarepta helping to offset high R&D expenditures, which reached $162.4 million in Q3 FY2025 [4] Market Opportunity and Competitive Advantage - Arrowhead's market opportunity is significant, covering cardiometabolic, obesity, and emerging CNS indications, with the TRiM™ delivery platform offering low-frequency dosing and the ability to target novel genes [5] - Near-term catalysts include the PDUFA decision for plozasiran in FCS, sHTG trial readouts, milestone payments, and data from early obesity and CNS programs, positioning Arrowhead for potential value creation and long-term growth [5]